Alnylam Receives Intent-to-Grant Notice for European Patent Application

The patent includes 19 claims related to the use of dsRNA for RNAi, including methods of reducing the expression of a gene, including those of mammalian or viral origin, with dsRNAs between 21 and 23 nucleotides in length, according to Alnylam.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.